secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001140361-26-000906
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA prelim FY2025 rev ~$510-511M, raises FY2026 rev/EBITDA guidance, targets >$1.1B by 2029
--------------------------------------------------------------------------------

- Preliminary FY2025 total revenue ~$510-511M, meeting or exceeding prior guidance. Cash grew to ~$88M with ~$40M Q4 operating cash flow.
- FY2026 revenue guidance raised to ~$635M (from $630M); FY2026 adjusted EBITDA raised to ~$360M (from $355M). Adjusted net income reiterated at ~$255M.
- FY2027 revenue guided ~$775M, adjusted net income ~$315M, adjusted EBITDA ~$455M.
- Long-term targets: >$1.1B revenue and >$700M adjusted EBITDA by FY2029. Yield-enhanced production now routine, 2026 first full year of monetization.
- Divested three plasma centers for $12M, secured long-term supply agreements, expects accretive cost savings from strategic repositioning.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036126000906/0001140361-26-000906-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036126000906/ef20062685_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-000906

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer